ImmunityBio Inc. (NASDAQ:IBRX) has a beta value of 2.06 and has seen 1.06 million shares traded in the last trading session. The company, currently valued at $4.53B, closed the last trade at $10.95 per share which meant it lost -$0.63 on the day or -5.44% during that session. The IBRX stock price is -314.79% off its 52-week high price of $45.42 and 44.93% above the 52-week low of $6.03. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.94 million shares traded. The 3-month trading volume is 1.08 million shares.
The consensus among analysts is that ImmunityBio Inc. (IBRX) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
ImmunityBio Inc. (NASDAQ:IBRX) trade information
Sporting -5.44% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the IBRX stock price touched $10.95 or saw a rise of 8.67%. Year-to-date, ImmunityBio Inc. shares have moved -17.85%, while the 5-day performance has seen it change -3.27%. Over the past 30 days, the shares of ImmunityBio Inc. (NASDAQ:IBRX) have changed -3.61%. Short interest in the company has seen 9.51 million shares shorted with days to cover at 11.96.
Wall Street analysts have a consensus price target for the stock at $25.00, which means that the shares’ value could jump 56.2% from current levels. The projected low price target is $25.00 while the price target rests at a high of $25.00. In that case, then, we find that the current price level is -128.31% off the targeted high while a plunge would see the stock gain -128.31% from current levels.
ImmunityBio Inc. (IBRX) estimates and forecasts
The company’s shares have lost -61.28% over the past 6 months, compared to 7.50% for the industry. Revenue growth from the last financial year stood is estimated to be -9.90%.
1 analysts offering their estimates for the company have set an average revenue estimate of $339k for the current quarter. 1 have an estimated revenue figure of $20k for the next quarter concluding in Sep 2021.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 23.10% over the past 5 years. Earnings growth for 2021 is a modest -27.80% while over the next 5 years, the company’s earnings are expected to decrease by -1.70%.
ImmunityBio Inc. is expected to release its next earnings report in October this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunityBio Inc. (NASDAQ:IBRX)’s Major holders
Insiders own 80.98% of the company shares, while shares held by institutions stand at 7.31% with a share float percentage of 38.42%. Investors are also buoyed by the number of investors in a company, with ImmunityBio Inc. having a total of 190 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 5.56 million shares worth more than $79.4 million. As of Jun 29, 2021, Vanguard Group, Inc. (The) held 1.42% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 5.27 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $75.3 million and represent 1.35% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and iShares Russell 2000 ETF. As of Jun 29, 2021, the former fund manager holds about 0.76% shares in the company for having 2.98 million shares of worth $42.58 million while later fund manager owns 1.52 million shares of worth $21.73 million as of Jun 29, 2021, which makes it owner of about 0.39% of company’s outstanding stock.